Stilla Technologies from France has received 16 million euros of investment for the sale and development of a high-precision polymerase chain reaction system (PCR) for the quantitative analysis of nucleic acids.
Attracting investment was carried out with the support of Illumina Ventures. With the help of attracted funds, Stilla Technologies plans to accelerate sales of its PCR technology, launch a second product and begin clinical trials of its diagnostic applications.
Founded in 2013, Stilla Technologies has developed a system for DNA quantification based on digital PCR technology, which is known for higher accuracy and sensitivity than other PCR methods.
The Naica system developed by Stilla aims to improve digital PCR technology. Digital PCR makes the analysis of complex samples much simpler and more accurate. And the Naica system simplifies the digital PCR itself.
This technology is also designed to simultaneously detect three different DNA sequences from a single sample using different fluorescent colors to identify each of them. This feature opens up possibilities in diagnostic applications, the first of which will be in oncology.
The Naica system is used to monitor cancer patients with simple blood tests by targeting clinically significant mutations, such as EGFR mutations for patients with lung cancer.
Other technology applications are prenatal research and detection of GMOs.
The company also plans to release a second-generation product, the exact characteristics of which have not yet been disclosed, but company representatives noted that it is designed to increase throughput, the ability to analyze several sequences simultaneously and integrate into automated laboratory workflows.
Illumina currently dominates the gene sequencing market. The company owns several gene sequencing firms, including Solexa, a British company that first introduced sequencing in the next generation.